Ovid Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on December 17, 2020, by Ovid Therapeutics Inc., a Delaware corporation. The report details compensation arrangements approved by the Compensation Committee for the Company's named executive officers (NEOs) effective for the 2020 and 2021 fiscal periods.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation details.
Material Changes and Compensation Details
The Compensation Committee approved the following compensation packages for the NEOs:
| Executive | Title | 2020 Cash Bonus | 2021 Base Salary | 2021 Bonus Target | 2021 Option Grant |
|---|---|---|---|---|---|
| Jeremy M. Levin | CEO | $280,000 | $583,734 | 50% | 650,000 shares |
| Amit Rakhit | President & CMO | $200,000 | $520,000 | 40% | 200,000 shares |
| Timothy Daly | EVP, Finance & Controller | $154,000 | $400,400 | 40% | 125,000 shares |
Equity Award Terms:
- Exercise Price: $2.82 per share (closing price on December 17, 2020).
- Vesting Schedule: 25% vests on the one-year anniversary of the grant date; the remaining 75% vests in 36 equal monthly installments.
- Term: 10 years from the grant date.
- Condition: Vesting is subject to continued service with the Company.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, management commentary on business performance, or specific risk factors beyond the standard vesting conditions tied to continued employment.
Key Facts for Investor Verification
- Verify the total cash bonus payout of $634,000 for the three named executives for 2020.
- Confirm the aggregate increase in annual base salaries effective January 1, 2021.
- Review the dilution impact of the 975,000 new stock options granted at an exercise price of $2.82.
- Check the Company's 2017 Equity Incentive Plan to ensure sufficient shares were available for these grants.